Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2003
08/21/2003WO2003068156A2 Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome
08/21/2003WO2003068148A2 Treatment of sleep disorders using sleep target modulators
08/21/2003WO2003068147A2 Treatments for neurotoxicity in alzheimer’s disease
08/21/2003WO2003068146A2 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
08/21/2003WO2003068144A2 Cytotoxic agents
08/21/2003WO2003068140A2 Novel pyridazine derivatives, use of the same as medicaments, pharmaceutical compositions and method for producing the same
08/21/2003WO2003068008A1 Water-dispersible coenzyme q10 dry powders
08/21/2003WO2003067988A1 Aqueous antiseptic based on bispyridiniumalkanes
08/21/2003WO2003067979A1 Drugs to be used in organ transplantation
08/21/2003WO2003060142A9 Compositions and methods for controlled release
08/21/2003WO2003055913A3 Secreted protein
08/21/2003WO2003047579B1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
08/21/2003WO2003045906A3 Synthesis of 2-cyanoziridine-1-carboxamide
08/21/2003WO2003045227A3 Single nucleotide polymorphisms and combinations thereof predictive for paclitaxel responsiveness
08/21/2003WO2003043610A3 A process for manufacture of a sustained release composition containing microbe
08/21/2003WO2003039479A3 Polymeric thiol-linked prodrugs
08/21/2003WO2003039450A3 Improvements in or relating to inhibition of viruses
08/21/2003WO2003037890A3 Piperidines
08/21/2003WO2003032893A3 Assignment
08/21/2003WO2003030862A3 Anaesthetic compositions and method for their administration
08/21/2003WO2003028738A3 Anti-infectious carbohydrates
08/21/2003WO2003027075A3 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
08/21/2003WO2003026632A3 Substituted phenol compounds useful for anesthesia and sedation
08/21/2003WO2003024935A3 Substituted pyrazolyl compounds for the treatment of inflammation
08/21/2003WO2003020217A3 Novel pyrazole analogs acting on cannabinoid receptors
08/21/2003WO2003018549A3 Bicyclic compounds as inhibitors of chemokine binding to us28
08/21/2003WO2003013488A3 Methods and compositions for inhibiting rad51
08/21/2003WO2003007930A3 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
08/21/2003WO2003004006A8 Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
08/21/2003WO2003001887A3 Fused pyrimidines as d-alanyl-d-alanine ligase inhibitors
08/21/2003WO2002100847A3 Factor xa inhibitor
08/21/2003WO2002100329A3 Methods and compositions for helping the body resist the effects of the aging process
08/21/2003WO2002098459A3 USE OF IgM ANTIBODIES AGAINST dsDNA IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS
08/21/2003WO2002095027A3 Immunostimulatory oligodeoxynucleic molecules
08/21/2003WO2002094844A3 Antiviral nucleosides
08/21/2003WO2002089917A3 Dermatological formulations
08/21/2003WO2002089779A3 Combined preparation for the prophylaxis and/or therapy of nerve cell and/or glia cell damage using a novel method of treatment
08/21/2003WO2002088664A3 Control of compactability through crystallization
08/21/2003WO2002082075A3 Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
08/21/2003WO2002080898A3 Methods for treating hyperactive gastric motility
08/21/2003WO2002070544A3 Methods, compositions and kits for preserving antigenicity
08/21/2003WO2002064731B1 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
08/21/2003WO2002061090A3 Prokaryotically produced antibodies and uses thereof
08/21/2003WO2002058623A3 Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation
08/21/2003WO2002056022A3 Diagnostics, drug screening and treatment for cancer
08/21/2003WO2002046224A3 Compositions and methods relating to lung specific genes and proteins
08/21/2003WO2002046158A3 Piperidine/piperazine-type inhibitors of p38 kinase
08/21/2003WO2002044418A3 Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
08/21/2003WO2002040002A3 Method for modulation, stimulation, and inhibition of glutamate reuptake
08/21/2003WO2002039994A3 Methods for the treatment and prevention of urinary stone disease
08/21/2003WO2002036573A3 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
08/21/2003WO2002036162A3 Compositions for treatment of ocular neovascularization and neural injury
08/21/2003WO2002020722A9 Methods and compositions for in vitro targeting
08/21/2003WO2002020001A3 Two-component anti-emetic composition comprising dexamethasone and metoclopramide
08/21/2003WO2002013801A3 Method of treating the syndrome of coronary heart disease risk factors in humans
08/21/2003WO2002008446A9 Synthesis and antiviral evaluation of nucleic acid based (nab) libraries
08/21/2003WO2002002512A3 Compounds to treat alzheimer's disease
08/21/2003WO2001097794A3 Inhibitors of matriptase for the treatment of cancer
08/21/2003WO2001097753A3 Novel methods using pyridine derivatives
08/21/2003WO2001092581A3 Compositions and methods for the therapy and diagnosis of ovarian cancer
08/21/2003US20030159164 Animal feeds
08/21/2003US20030159158 Method for identifying an agonist of neuronal calcium sensor-1 (NCS-1), for therapy of CNS disorders
08/21/2003US20030158598 System for sustained-release delivery of anti-inflammatory agents from a coated medical device
08/21/2003US20030158459 Enhanced formulations for neutraliztion of chemical, biological and industrial toxants
08/21/2003US20030158424 Substituted alpha, beta-anellated butyrolactones
08/21/2003US20030158416 Neutralizing paroxetine hydrochloride in organic solvent, salt formation, crystallization or spray drying to form solvent-free
08/21/2003US20030158414 Process for preparing growth hormone secretagogues
08/21/2003US20030158409 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
08/21/2003US20030158381 Novel insulin/igf/relaxin family polypeptides and dnas thereof
08/21/2003US20030158376 Relaxin-like factor and methods and uses thereof
08/21/2003US20030158266 Particularly septic shock
08/21/2003US20030158265 Embedded into an oily matrix, an expectorant (e.g., guaifenesin); a surfactant (e.g., lecithin); a suspending agent (e.g., beeswax); and a suspension medium (e.g., soybean oil)
08/21/2003US20030158264 Embedded into an oily matrix, an expectorant (e.g., guaifenesin); a surfactant (e.g., lecithin); a suspending agent (e.g., beeswax); and a suspension medium (e.g., soybean oil)
08/21/2003US20030158263 Orally administrable pharmaceutical formulation
08/21/2003US20030158262 Ameliorating progression of amyotrophic lateral sclerosis
08/21/2003US20030158261 Reducing the likelihood of side effects associated with the administration of guanfacine or angrelide by administering along with both a pH dependent and a non-pH dependent sustained release agent
08/21/2003US20030158260 Halogenated N-phenyl-N'-benzoylurea derivatives for controlling a sea lice infestation on fish; e.g., 1-(4-chloro-3-(3-chloro-5-trifluoro-methyl-2-pyridyloxy)-phenyl)-3-(2,6 -difluorobenzoyl)urea
08/21/2003US20030158258 5-aminolevulinic acid ester solution; detection of fluorescent protoporphyrin IX
08/21/2003US20030158257 Administering a diglyceride, especially of omega 3 unsaturated fatty acids; dietary therapy for a diabetic patient
08/21/2003US20030158256 (Arylaminoaceamido)acetonitrile derivatives
08/21/2003US20030158255 Use of bismuth subgallate in prevention and/or reduction of skin deterioration
08/21/2003US20030158254 Linking an agent to a conjugate moiety that has a greater Vmax for a transporter expressed in plasma membranes of epithelial cells lining a human colon than the agent alone; delayed or sustained release
08/21/2003US20030158252 Especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa.
08/21/2003US20030158251 Administering an agent capable of inhibiting NADH quinone oxidoreductase 1 activity, such as dicumarol.
08/21/2003US20030158250 Agents correcting gene expression regulatory error
08/21/2003US20030158249 Is significantly more active against hepatocellular carcinoma cells than paclitaxel at concentrations of up to 1 mu M.
08/21/2003US20030158248 N-(2-(1-amidinopyrrol-3-yl)ethyl)-5,6-dihydroxy-1-(2-(2-methox y-3-sulfatopropionylamino)-3-chloro-4-methylvaleroyl)indole-2-carboxamide
08/21/2003US20030158247 Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor
08/21/2003US20030158246 For the treatment of prostaglandin mediated diseases, such as allergic asthma or rhinitis.
08/21/2003US20030158244 Methods of treatment using a gastric retained losartan dosage
08/21/2003US20030158243 Preparation and use of carbohydrate-based bicyclic ring structures with antimicrobial and cytostatic activity
08/21/2003US20030158242 Salt with a sugar substitute, especially saccharin, cyclamate or acesulfame.
08/21/2003US20030158241 Used for treatment of diabetes and a complication thereof, hyperlipidemia and a complication thereof, hyperuricemia, leukemia, and pancreatitis.
08/21/2003US20030158240 Methods for the treatment of primary headache disorders using prostanoid EP4 receptor antagonists, and assays for agents for such treatment
08/21/2003US20030158239 Reacting a selenourea and an alpha-haloacyl halide in a solvent and in the presence of a catalyst; useful as raw materials for drugs and agricultural chemicals
08/21/2003US20030158238 Treating diseases such as cancer, inflammatory disorders, restenosis,
08/21/2003US20030158237 Combination of antioxidant substances for the treatment of alzheimer's disease
08/21/2003US20030158236 Treating, e.g., an HIV infection.
08/21/2003US20030158235 Pyridine amido derivatives
08/21/2003US20030158234 Use for deferiprone
1 ... 5367 5368 5369 5370 5371 5372 5373 5374 5375 5376 5377 5378 5379 5380 5381 5382 5383 5384 5385 5386 5387 ... 7860